June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Fluorescein angiography in persistent retinopathy of prematurity
Author Affiliations & Notes
  • Clinton Warren
    Ophthalmology, Medical College of Wisconsin, Milwaukee, WI
  • Jonathon Young
    Ophthalmology, Medical College of Wisconsin, Milwaukee, WI
  • Mara R Goldberg
    Ophthalmology, Medical College of Wisconsin, Milwaukee, WI
  • Vesper Williams
    Ophthalmology, Medical College of Wisconsin, Milwaukee, WI
  • Thomas B Connor
    Ophthalmology, Medical College of Wisconsin, Milwaukee, WI
  • Deborah Costakos
    Ophthalmology, Medical College of Wisconsin, Milwaukee, WI
  • Footnotes
    Commercial Relationships Clinton Warren, None; Jonathon Young, None; Mara Goldberg, None; Vesper Williams, None; Thomas Connor, None; Deborah Costakos, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 979. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Clinton Warren, Jonathon Young, Mara R Goldberg, Vesper Williams, Thomas B Connor, Deborah Costakos; Fluorescein angiography in persistent retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):979.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

The current screening guidelines for retinopathy of prematurity (ROP) recommend screening cessation at a postmenstrual age (PMA) of 45 weeks in the absence of prior type 1 ROP. Some infants may demonstrate persistent avascular retina, peripheral neovascularization, and other vascular abnormalities beyond a PMA of 45 weeks. The natural history of retinal non-perfusion and neovascularization among this population is not well understood and may predispose to the development of late exudative retinopathy and tractional retinal detachment. We performed a retrospective study to analyze the angiographic findings among infants that demonstrated persistent ROP in Zone III and peripheral Zone II after a PMA of 45 weeks.

 
Methods
 

This is a retrospective, observational study of infants with persistent ROP in Zone III and peripheral Zone II after a PMA of 45 weeks. ROP screening was performed by a single examiner at the Children's Hospital of Wisconsin using indirect ophthalmoscopy and 360° scleral depression. Fundus photos and fluorescein angiograms obtained using a RetCam3 digital imaging system were reviewed. Patient records were also reviewed for gender, gestational age, birth weight, medical history, and oxygen status.

 
Results
 

A total of 4 premature infants (8 eyes) were identified to have persistent ROP in Zone III and/or peripheral Zone II after a PMA of 45 weeks. Three of the subjects were male and one female. The mean birth weight was 674.5 grams. The mean gestational age was 24.6 weeks. The mean PMA at time of imaging was 51.25 weeks. Indirect ophthalmoscopy demonstrated Zone III Stage 3 ROP in 2 patients and peripheral Zone II Stage 3 ROP in 2 patients. Plus disease was absent in all four subjects. Peripheral avascular retina was demonstrated by fluorescein angiography in all four subjects. Fluorescein angiography also revealed areas of peripheral neovascularization with focal sites of active leakage.

 
Conclusions
 

Fluorescein angiography can reveal areas of peripheral neovascularization and active leakage among infants with persistent ROP, findings not easily appreciated by indirect ophthalmoscopy or color fundus photography. This may suggest that infants with persistent ROP may benefit from extended surveillance or laser ablation to reduce the risk of late complications.  

 
Fluorescein angiography of an infant at 52 weeks, demonstrating peripheral neovascularization in Zone III with focal sites of active leakage.
 
Fluorescein angiography of an infant at 52 weeks, demonstrating peripheral neovascularization in Zone III with focal sites of active leakage.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×